Five Questions Your Clients Will Ask About Psychedelics This Year

A new client, partway through an intake, discloses that she microdoses psilocybin. Nobody asked. She says it a little defensively, the way people disclose things they've been judged for before, and then she watches your face to find out whether therapy is still a safe place for her.

That moment is happening in more offices every month, and it marks a shift worth naming. Client questions about psychedelic therapy used to be hypothetical: is this stuff real medicine? Now they're logistical: how do I get it, is that clinic legitimate, is the thing I already did okay to talk about here. Roughly 5% of US adults reported using a psychedelic in a recent year, the regulatory landscape is moving fast, and most therapists' graduate training covered none of it. You don't need to become a psychedelic specialist. You do need accurate answers, because your clients are currently getting their answers from TikTok and from companies with something to sell.

Here are the five questions I hear most, with the answers I'd actually give.

Closer than ever, but not yet, and approval won't mean what most clients picture. Compass Pathways' second Phase 3 trial of its psilocybin formulation met its primary endpoint in treatment-resistant depression this year, and in April the FDA granted priority review vouchers to three psychedelic programs, including two psilocybin products. A 2026 executive order directs agencies to accelerate review and to begin rescheduling proceedings once a psychedelic earns approval. The track is genuinely fast by FDA standards.

What approval would actually deliver: a specific product, for a specific diagnosis, delivered under monitored conditions that current trial protocols measure in six-to-eight-hour supervised sessions. Insurance coverage, trained providers, and locations are all unsolved.

What I'd say to a client: "Possibly within the next year or two for treatment-resistant depression, but it will arrive as a tightly controlled medical procedure, probably expensive at first, not a prescription you fill."

This is the question where independent information is hardest for clients to find, because most of what ranks in a search is written by the companies selling the service. The honest answer has three parts.

First, it's legal: ketamine can be prescribed off-label for depression, and telehealth prescribing without an in-person visit is allowed under DEA flexibilities that currently run through December 31, 2026.

Second, the model has real gaps. A STAT analysis of six months of patient discussion in at-home ketamine communities found people acting as their own safety monitors, escalating doses, and lacking real-time support during sessions. The FDA has also increased scrutiny of the compounded ketamine these services rely on.

Third, ketamine carries real misuse potential, which a client dosing alone in a bedroom is managing without help.

What I'd say to a client: "It's legal, and some people are helped. I'd want to know: who monitors you during a session, what's the protocol if you have a frightening experience, how is your dose decided and adjusted, and is any therapy attached, or is it medication alone?" Those four questions tell you most of what you need to know about a specific service, and asking them keeps you in the conversation rather than outside it.

Years, not months, and anyone who tells a client otherwise is selling something. MDMA-assisted therapy (pharmaceutical MDMA in a structured clinical protocol, not street ecstasy, which varies wildly in content and purity) was rejected by the FDA in 2024. The agency's now-public Complete Response Letter detailed concerns about trial conduct and the difficulty of blinding. After meeting with the FDA in January 2026, the sponsor committed to an entirely new Phase 3 trial plus an independent review of its prior data. No public timeline exists.

What I'd say to a client: "The research showed promise for PTSD, the application had real problems, and the company has to run a new full-scale trial. Realistically you're looking at years. If someone is offering you MDMA therapy in the US right now, it's either a clinical trial or it's illegal, and that's worth knowing before you're in the room."

The map has exactly three kinds of territory right now. State-regulated psilocybin access: Oregon (supervised adult sessions at licensed service centers, no diagnosis required), Colorado (licensed healing centers), and, beginning as soon as December 2026, New Mexico's medical program for specific qualifying conditions. Legal everywhere by prescription: ketamine, off-label. Everything else: psilocybin, MDMA, LSD, and most other psychedelics remain federally Schedule I and illegal in the other 47 states, though some cities have deprioritized enforcement, which is not the same thing as legal.

What I'd say to a client: the accurate two sentences for your state, delivered without editorializing. And for yourself, not the client: what you can legally do in your own role varies by state and license, and scope questions belong with your licensing board, not a blog post, including this one.

This one arrives after the fact, and it's the question that most rewards a therapist who can stay steady. A client returns from Oregon, or Mexico, or a friend's living room, with an experience that felt significant and no idea what to do with it. The single most useful thing you can offer is not an opinion about the decision they already made. It's **integration**: the unglamorous work of connecting what happened to how they actually live, which is where lasting change happens or doesn't.

You don't need psychedelic specialization to do this. You need your existing clinical skills, a genuinely nonjudgmental stance (clients scan hard for disapproval here, like the woman in the intake), and a basic map of what to listen for: material that's emotionally live, meaning the client is constructing, sleep and mood in the weeks after, and any experience that left them frightened or destabilized, which deserves the same careful assessment any acute distress would.

What I'd say to a client: "Tell me about it. We can work with this."

Notice what these answers have in common: none of them is "don't," and none of them is "go ahead." Clients who are priced out of legal options, or just impatient, are making these decisions with or without us. The clinical job is the harm reduction job: stay accurate, stay in the conversation, and be the one person in the client's life who has neither moral panic nor a product to sell.

If a client has already used psychedelics and you want a structured place to start, I wrote a free guide for exactly this situation.